pyrazinamide has been researched along with prothionamide in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (31.03) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 9 (31.03) | 24.3611 |
| 2020's | 7 (24.14) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Springett, VH | 1 |
| Bialik, IB; Khutorskaia, VD; Mamolat, AS | 1 |
| Schmidt, M | 1 |
| Lode, H; Schaberg, T | 1 |
| Holdiness, MR | 1 |
| Felten, MK | 1 |
| Chang, SC; Hong, YP; Jin, BW; Kim, SC; Kim, SJ; Park, CD | 1 |
| Kleeberg, HH | 1 |
| Engelhard, M; Layer, P | 1 |
| Cowie, RL; Langton, ME | 1 |
| Opl, G; Sighart, H; Weirich, H | 1 |
| Han, L; Lee, DH; Lee, WC; Mitnick, CD; Park, SK; Seung, KJ | 1 |
| Dovgaliuk, IF; Ovchinnikova, IuE; Starshinova, AA | 1 |
| Chiang, CY; Madan, J; Meredith, SK; Nunn, AJ; Phillips, PP; Rusen, ID; Squire, SB; Torrea, G; Van Deun, A | 1 |
| Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A | 1 |
| Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS | 1 |
| Adebola, SO; Adedeji, TO; Adefuye, BO; Oladeji, SM; Sogebi, OA | 1 |
| Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS | 1 |
| Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM | 1 |
| Ding, X; Fan, G; Ho, CM; Jiang, J; Lan, L; Lou, Y; Wu, S | 1 |
| Cho, HJ; Kang, MW; Kim, J; Koh, WJ; Lim, YJ; Song, CH | 1 |
| Dolgushin, MV | 1 |
| Alffenaar, JC; Bruchfeld, J; Davies Forsman, L; Hu, Y; Jongedijk, EM; Kuhlin, J; Niward, K; Paues, J; Schön, T; Xu, B; Zheng, R; Zheng, X | 1 |
| Bate, PNN; Chiwala, G; Fang, C; Guan, P; Hameed, HMA; Hu, J; Khan, SA; Liu, J; Liu, Z; Mugweru, JN; Tan, S; Tan, Y; Wang, B; Yusuf, B; Zhang, T; Zhong, N | 1 |
| Choi, J; Jang, SH; Jeong, HE; Jung, SY; Oh, IS; Shin, JY; Son, H | 1 |
| Jiang, H; Li, X; Niu, Q; Xing, Z; Xu, J | 1 |
| Chen, L; Clemens, DL; Ding, X; Gu, J; Gui, X; Hao, X; He, Y; Ho, CM; Horwitz, MA; Lee, BY; Liu, Y; Lou, H; Ma, J; Sha, W; Sun, Q; Yang, H; Yao, L; Ying, R; Zheng, X | 1 |
2 review(s) available for pyrazinamide and prothionamide
| Article | Year |
|---|---|
[Therapy of tuberculosis].
Topics: Antitubercular Agents; Contraindications; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Prothionamide; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis | 1990 |
Adverse cutaneous reactions to antituberculosis drugs.
Topics: Acne Vulgaris; Adult; Amikacin; Antitubercular Agents; Drug Hypersensitivity; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Male; Middle Aged; Pellagra; Pigmentation Disorders; Prothionamide; Pyrazinamide; Rifampin; Skin Diseases; Streptomycin; Thioacetazone | 1985 |
6 trial(s) available for pyrazinamide and prothionamide
| Article | Year |
|---|---|
Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.
Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Humans; Male; Prothionamide; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1988 |
Pulmonary tuberculosis treated with isoprodian and rifampicin or pyrazinamide.
Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Dapsone; Drug Combinations; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Patient Compliance; Prothionamide; Pyrazinamide; Radiography; Recurrence; Rifampin; Sputum; Tuberculosis, Pulmonary | 1987 |
[Comparative study of the treatment of pulmonary tuberculosis with isoprodian and pyrazinamide as well as isoprodian and rifampicin].
Topics: Adult; Aged; Antitubercular Agents; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Isonicotinic Acids; Male; Middle Aged; Prothionamide; Pyrazinamide; Radiography; Rifampin; Sputum; Time Factors; Tuberculosis, Pulmonary | 1982 |
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Moxifloxacin; Prothionamide; Pyrazinamide; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Area Under Curve; Cycloserine; Drug Monitoring; Fluoroquinolones; Healthy Volunteers; Humans; Kanamycin; Levofloxacin; Male; Moxifloxacin; Prothionamide; Pyrazinamide; Streptomycin; Young Adult | 2015 |
Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial.
Topics: Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Humans; Isoniazid; Prothionamide; Pyrazinamide; Treatment Outcome; Tuberculosis | 2023 |
21 other study(ies) available for pyrazinamide and prothionamide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
The treatment of tuberculosis.
Topics: Aminosalicylic Acids; Capreomycin; Ethambutol; Ethionamide; Humans; Isoniazid; Prothionamide; Pyrazinamide; Rifampin; Streptomycin; Thioacetazone; Tuberculosis | 1975 |
[Current questions in the treatment of patients with chronic destructive pulmonary tuberculosis].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Kanamycin; Prothionamide; Pyrazinamide; Tuberculosis, Pulmonary; Viomycin | 1976 |
[Therapy of pulmonary tuberculosis].
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Inpatients; Isoniazid; Male; Outpatients; Pregnancy; Prothionamide; Pyrazinamide; Rifampin; Streptomycin; Time Factors; Tuberculosis, Pulmonary | 1992 |
Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dapsone; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Microbial Sensitivity Tests; Middle Aged; Prothionamide; Pyrazinamide; Rifampin; Sputum; Tuberculosis, Pulmonary | 1989 |
[Tuberculostatics-induced systemic lupus erythematosus].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Lupus Erythematosus, Systemic; Middle Aged; Prothionamide; Pyrazinamide; Streptomycin; Tuberculosis, Pulmonary | 1986 |
Failure of a prothionamide-containing oral antituberculosis regimen.
Topics: Administration, Oral; Antitubercular Agents; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Isonicotinic Acids; Male; Patient Compliance; Prothionamide; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1985 |
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Cohort Studies; Cycloserine; Female; Humans; Kanamycin; Korea; Male; Middle Aged; Ofloxacin; Prothionamide; Pyrazinamide; Retrospective Studies; Self Administration; Streptomycin; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2004 |
[Optimization of chemotherapy regimens in children with primary pulmonary tuberculosis].
Topics: Adolescent; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Cycloserine; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Prothionamide; Pyrazinamide; Radiography, Thoracic; Rifampin; Streptomycin; Time Factors; Tuberculosis, Lymph Node; Tuberculosis, Pulmonary | 2009 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence Intervals; Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Kanamycin; Male; Medication Adherence; Middle Aged; Odds Ratio; Prospective Studies; Prothionamide; Pyrazinamide; Risk Assessment; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2015 |
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; Coinfection; Comorbidity; Cycloserine; Diabetes Mellitus; Female; Hearing Loss; HIV Infections; Humans; Kanamycin; Levofloxacin; Male; Middle Aged; Nigeria; Prospective Studies; Prothionamide; Pyrazinamide; Risk Factors; Time Factors; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort Studies; Comorbidity; Cycloserine; Ethambutol; Female; Fluoroquinolones; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Prothionamide; Pyrazinamide; Republic of Korea; Retrospective Studies; Rifampin; Severity of Illness Index; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |
Simultaneous determination of the potent anti-tuberculosis regimen-Pyrazinamide, ethambutol, protionamide, clofazimine in beagle dog plasma using LC-MS/MS method coupled with 96-well format plate.
Topics: Animals; Antitubercular Agents; Calibration; Chromatography, Liquid; Clofazimine; Dogs; Ethambutol; Prothionamide; Pyrazinamide; Reproducibility of Results; Tandem Mass Spectrometry | 2019 |
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Cycloserine; Extensively Drug-Resistant Tuberculosis; Female; Humans; Lung; Macrophage Activation; Macrophages; Male; Middle Aged; Mycobacterium tuberculosis; Prothionamide; Pyrazinamide; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2020 |
Cytochemical Evaluation of the Toxic Effects of Combined Antituberculosis Substances on Metabolic State of Blood Lymphocytes.
Topics: Acid Phosphatase; Administration, Oral; Animals; Animals, Outbred Strains; Antitubercular Agents; Drug Combinations; Esterases; Ethambutol; Fluoroquinolones; Gene Expression; Glycerolphosphate Dehydrogenase; Isoniazid; L-Lactate Dehydrogenase; Lymphocytes; Male; Primary Cell Culture; Prothionamide; Pyrazinamide; Rats; Rifampin; Succinate Dehydrogenase | 2020 |
Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.
Topics: Adult; Chromatography, Liquid; Drug Monitoring; Ethambutol; Female; Fluoroquinolones; Humans; Limit of Detection; Linear Models; Male; Prothionamide; Pyrazinamide; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
Topics: Amikacin; Animals; Antigens, Bacterial; Antitubercular Agents; BCG Vaccine; Disease Models, Animal; Drug Resistance, Bacterial; Levofloxacin; Mice, Inbred BALB C; Mice, SCID; Mycobacterium bovis; Mycobacterium tuberculosis; Plasmids; Prothionamide; Pyrazinamide; Tuberculosis, Pulmonary; Vaccines, Synthetic; Virulence | 2021 |
Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea.
Topics: Antitubercular Agents; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Prothionamide; Pyrazinamide; Republic of Korea; Streptomycin; Tuberculosis, Multidrug-Resistant | 2022 |
Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Topics: Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Humans; Levofloxacin; Linezolid; Mycobacterium tuberculosis; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Prothionamide; Pyrazinamide; Reactive Oxygen Species; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |